期刊
NATURE MEDICINE
卷 26, 期 10, 页码 1623-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-1038-6
关键词
-
资金
- Cancer ImmunoTherapy Accelerator award from CRUK
- CRUK City of London Major Cancer Centre studentship
- Wellcome Trust [106292/Z/14/Z, FC001093]
- Rosetrees Trust
- King's Together Seed Fund
- Gamma Delta Therapeutics
- John Black Charitable Foundation
- Francis Crick Institute
- Cancer Research UK [FC001093]
- MRC [FC001093]
- NIHR Clinician Scientist Award [CS-2016-16-011]
- NIHR Biomedical Research Centre for the Infectious Diseases Biobank [RJ112/N027]
- NIHR Biomedical Research Centre for support of Infection and Immunity [RJ112/N027]
- EMBO ALTF [198-2018]
- Irvington Fellowship-Cancer Research Institute
- National Institute of Academic Anaesthesia BJA-RCOA PhD Fellowship [WKR0-2018-0047]
- NIHR Fellowship
- Clinical Immunology Research Fund for the King's College Hospital Charitable Trust
- UK MRC [MR/N013700/2]
- EMBL core funding
- European Union's Horizon 2020 Research and Innovation Programme [730879]
- Estonian Research Council [PRG377]
- Cancer Research UK
- Versus Arthritis [20265] Funding Source: researchfish
- Rosetrees Trust [M943] Funding Source: researchfish
- The Francis Crick Institute [10729, 10093, 10794, 10787] Funding Source: researchfish
- Wellcome Trust [106292/Z/14/Z] Funding Source: researchfish
A common immune signature in the blood of patients with COVID-19, who are otherwise clinically heterogeneous, sheds light into the pathogenesis and clinical progression of the disease. Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据